Barry Hafkin
Directeur Technique/Scientifique/R&D chez MicuRx Pharmaceuticals, Inc.
Profil
Barry Hafkin is currently the Chief Medical Officer & Executive Vice President at MicuRx Pharmaceuticals, Inc. He previously worked as the Chief Scientific Officer at Middlebrook Pharmaceuticals, Inc. and as the Chief Medical Officer at Affinium Pharmaceuticals Ltd.
Hafkin holds a doctorate degree from The University of Texas at Austin and an undergraduate degree from the University of Houston.
Postes actifs de Barry Hafkin
| Sociétés | Poste | Début |
|---|---|---|
MicuRx Pharmaceuticals, Inc.
 MicuRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MicuRx Pharmaceuticals, Inc. is a holding company, which engages in the discovery, development, and commercialization of safe and effective antimicrobial therapeutics for multidrug-resistant superbag infections. The company was founded by Zheng Yu Yuan and Mikhail Fedorovich Gordeev in March 2007 and is headquartered in Pudong, China. | Directeur Technique/Scientifique/R&D | 02/11/2015 |
Anciens postes connus de Barry Hafkin
| Sociétés | Poste | Fin |
|---|---|---|
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Directeur Technique/Scientifique/R&D | - |
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Directeur Technique/Scientifique/R&D | - |
Formation de Barry Hafkin
| The University of Texas at Austin | Doctorate Degree |
| University of Houston | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Middlebrook Pharmaceuticals, Inc.
Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Health Technology |
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
MicuRx Pharmaceuticals, Inc.
MicuRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MicuRx Pharmaceuticals, Inc. is a holding company, which engages in the discovery, development, and commercialization of safe and effective antimicrobial therapeutics for multidrug-resistant superbag infections. The company was founded by Zheng Yu Yuan and Mikhail Fedorovich Gordeev in March 2007 and is headquartered in Pudong, China. | Health Technology |